
### [NCIT:C27632](http://purl.obolibrary.org/obo/NCIT_C27632)
**Label:** Transplant-Related Malignant Neoplasm

**Subclasses:** [NCIT:C27640](http://purl.obolibrary.org/obo/NCIT_C27640) (Transplant-Related Kaposi Sarcoma), [NCIT:C27695](http://purl.obolibrary.org/obo/NCIT_C27695) (EBV-Related Clonal Post-Transplant Lymphoproliferative Disorder), [NCIT:C7249](http://purl.obolibrary.org/obo/NCIT_C7249) (Immunoblastic Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7238](http://purl.obolibrary.org/obo/NCIT_C7238) (Monomorphic T/NK-Cell Post-Transplant Lymphoproliferative Disorder), [NCIT:C7248](http://purl.obolibrary.org/obo/NCIT_C7248) (Centroblastic Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7237](http://purl.obolibrary.org/obo/NCIT_C7237) (Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder), [NCIT:C7239](http://purl.obolibrary.org/obo/NCIT_C7239) (Hodgkin-Like Post-Transplant Lymphoproliferative Disorder), [NCIT:C7245](http://purl.obolibrary.org/obo/NCIT_C7245) (Burkitt-Like Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C27638](http://purl.obolibrary.org/obo/NCIT_C27638) (Transplant-Related Renal Cell Carcinoma), [NCIT:C7233](http://purl.obolibrary.org/obo/NCIT_C7233) (Monomorphic Post-Transplant Lymphoproliferative Disorder), [NCIT:C27637](http://purl.obolibrary.org/obo/NCIT_C27637) (Transplant-Related Lung Carcinoma), [NCIT:C7244](http://purl.obolibrary.org/obo/NCIT_C7244) (Burkitt Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7247](http://purl.obolibrary.org/obo/NCIT_C7247) (Anaplastic Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C27639](http://purl.obolibrary.org/obo/NCIT_C27639) (Transplant-Related Hematologic Malignancy), [NCIT:C7246](http://purl.obolibrary.org/obo/NCIT_C7246) (Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7241](http://purl.obolibrary.org/obo/NCIT_C7241) (Plasmacytoma-Like Post-Transplant Lymphoproliferative Disorder), [NCIT:C27634](http://purl.obolibrary.org/obo/NCIT_C27634) (Transplant-Related Bladder Urothelial Carcinoma), [NCIT:C7240](http://purl.obolibrary.org/obo/NCIT_C7240) (Plasma Cell Post-Transplant Lymphoproliferative Disorder), [NCIT:C27633](http://purl.obolibrary.org/obo/NCIT_C27633) (Transplant-Related Carcinoma), [NCIT:C7243](http://purl.obolibrary.org/obo/NCIT_C7243) (Classical Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder), [NCIT:C27636](http://purl.obolibrary.org/obo/NCIT_C27636) (Transplant-Related Skin Squamous Cell Carcinoma), [NCIT:C7242](http://purl.obolibrary.org/obo/NCIT_C7242) (Plasma Cell Myeloma Post-Transplant Lymphoproliferative Disorder), [NCIT:C27635](http://purl.obolibrary.org/obo/NCIT_C27635) (Transplant-Related Hepatocellular Carcinoma), 

**Class expressions from DL-Learner:**

- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36554](http://purl.obolibrary.org/obo/NCIT_C36554) (del(3p21-23)))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36553](http://purl.obolibrary.org/obo/NCIT_C36553) (Gain of Chromosome 1q21-31))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36552](http://purl.obolibrary.org/obo/NCIT_C36552) (Gain of Chromosome 1p31))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36551](http://purl.obolibrary.org/obo/NCIT_C36551) (Gain of Chromosome 7q32))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36550](http://purl.obolibrary.org/obo/NCIT_C36550) (Gain of Chromosome 7p))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36549](http://purl.obolibrary.org/obo/NCIT_C36549) (Loss of Chromosome 11))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36548](http://purl.obolibrary.org/obo/NCIT_C36548) (Loss of Chromosome 2q))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36547](http://purl.obolibrary.org/obo/NCIT_C36547) (Loss of Chromosome 2p))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36545](http://purl.obolibrary.org/obo/NCIT_C36545) (Gain of Chromosome 5q))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36542](http://purl.obolibrary.org/obo/NCIT_C36542) (Loss of Chromosome 16))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36540](http://purl.obolibrary.org/obo/NCIT_C36540) (Rearrangement of 8q11-13))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36539](http://purl.obolibrary.org/obo/NCIT_C36539) (Gain of Chromosome X))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36538](http://purl.obolibrary.org/obo/NCIT_C36538) (del(6q23)))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C36536](http://purl.obolibrary.org/obo/NCIT_C36536) (Loss of Chromosome 13))) 60.82%


